Who is sponsoring NCT05704192?

NCT05704192 is sponsored by Zhongda Hospital.

What drugs are being tested in NCT05704192?

Interventions in NCT05704192: TACE ± Systemic therapy.

What condition does NCT05704192 study?

NCT05704192 studies Hepatocellular Carcinoma, Portal Hypertension.

Is NCT05704192 still recruiting?

NCT05704192 is currently status unknown. Last updated 31 May 2023.

Last reviewed 2023-05-31 · How we verify

NCT05704192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

Status unknown Last updated 31 May 2023

What this trial tests

trial testing TACE ± Systemic therapy in Hepatocellular Carcinoma in 373 participants. Status unknown.

Timeline

4 May 2023

Primary endpoint
30 June 2023

31 December 2023

Quick facts

Lead sponsor	Zhongda Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	373
Start date	4 May 2023
Primary completion	30 June 2023
Estimated completion	31 December 2023
Sites	2 locations across China

Drugs / interventions tested

TACE ± Systemic therapy

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

Zhongda Hospital

Who can join

18 and older, any sex, with Hepatocellular Carcinoma or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the impact of non-invasive CT-based Hepatic Venous Pressure Gradient (HVPG) assessment on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
Chan YT, Zhang C, Wu J, Lu P, et al · · 2024 · cited 158× · PMID 39242496 · DOI 10.1186/s12943-024-02101-z

Verify or expand the search:

Other trials of TACE ± Systemic therapy

Trials testing the same drug.

NCT05703750 — Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) · unknown

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhongda Hospital trials

Trials by the same sponsor.

NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05704192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
Last refreshed: 31 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05704192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing